Letter

Guidelines on neuraminidase inhibitors in children are not supported by evidence

BMJ 2004; 328 doi: 10.1136/bmj.328.7433.227 (Published 22 January 2004)
Cite this as: BMJ 2004;328:227.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Mkael Symmonds, preregistration house officer (mkael@doctors.org.uk),
  2. Nicholas J Matheson, preregistration house officer,
  3. Anthony Harnden, university lecturer
  1. Department of Surgery, Ayr Hospital, Ayr KA6 6DX
  2. Department of Medicine, John Radcliffe Hospital, Oxford OX3 9DU
  3. Department of Primary Health Care, Institute of Health Sciences, Oxford OX3 7LF

    EDITOR—Guidelines from the National Institute for Clinical Excellence (NICE) on the use of neuraminidase inhibitors recommend oseltamivir for the treatment of at risk children with influenza-like illness of fewer than 48 hours' duration—for example, those with underlying chronic respiratory disease.1 The drug is not recommended for otherwise healthy children.

    In our systematic review on the use of neuraminidase …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular